Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.

ABSTRACT:

Importance

Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed.

Objective

To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19.

Design, setting, and participants

The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients' symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate d

SUBMITTER: Lim SCL 

PROVIDER: S-EPMC8980926 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature